Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001193125-18-022393
Filing Date
2018-01-29
Accepted
2018-01-29 06:13:06
Documents
13

Document Format Files

Seq Description Document Type Size
1 424B4 d475892d424b4.htm 424B4 1595882
2 GRAPHIC g475892g07q36.jpg GRAPHIC 58587
3 GRAPHIC g475892g14y95.jpg GRAPHIC 68176
4 GRAPHIC g475892g16k55.jpg GRAPHIC 77969
5 GRAPHIC g475892g16r29.jpg GRAPHIC 119380
6 GRAPHIC g475892g16s95.jpg GRAPHIC 115059
7 GRAPHIC g475892g21d19.jpg GRAPHIC 99976
8 GRAPHIC g475892g74c97.jpg GRAPHIC 60787
9 GRAPHIC g475892g77j27.jpg GRAPHIC 60355
10 GRAPHIC g475892g79t13.jpg GRAPHIC 76946
11 GRAPHIC g475892g80i74.jpg GRAPHIC 62158
12 GRAPHIC g475892g92q50.jpg GRAPHIC 39693
13 GRAPHIC g475892g99k81.jpg GRAPHIC 80747
  Complete submission text file 0001193125-18-022393.txt   2864711
Mailing Address 501 BOYLSTON STREET SUITE 6102 BOSTON MA 02116
Business Address 501 BOYLSTON STREET SUITE 6102 BOSTON MA 02116 617-482-2333
resTORbio, Inc. (Filer) CIK: 0001720580 (see all company filings)

EIN.: 813305277 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-222373 | Film No.: 18553421
SIC: 2834 Pharmaceutical Preparations